Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 9:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Detemir Clear all
Completed Phase 4 Interventional Results available

Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

NCT03620890
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Neutral Protamine Hagedorn (NPH), Detemir insulin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

NCT00773279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
FlexTouch®, FlexPen®
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
65
States / cities
Burlingame, California • Concord, California • Encino, California + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 2 Interventional Results available

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

NCT01595646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Saline, Insulin detemir, Insulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

NCT00487240
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro Protamine Suspension, Insulin Levemir
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Idaho Falls, Idaho • Springfield, Illinois • Topeka, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

NCT00106366
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
68
States / cities
Birmingham, Alabama • Vestavia Hills, Alabama • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 2 Interventional

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days

NCT01547169
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Placebo Comparator, insulin detemir
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 15, 2026, 9:49 PM EDT
Not listed No phase listed Observational

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

NCT05161429
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

NCT01186003
View directory record Official record
Conditions
Diabetes
Interventions
Detemir
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 4 Interventional

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 15, 2026, 9:49 PM EDT
Active, not recruiting Not applicable Interventional

Insulin Detemir in Obesity Management

NCT01239550
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Detemir
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
31 Years to 60 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Not applicable Interventional Results available

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

NCT01232946
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
liraglutide, insulin detemir, liraglutide plus insulin detemir
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 15, 2026, 9:49 PM EDT
Withdrawn Phase 4 Interventional

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

NCT02811484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Detemir: Role in Type 1 Diabetes

NCT00564395
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Detemir mixed with RAI injection, Insulin Detemir and RAI injection
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
10 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

NCT01966978
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00909480
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
71
States / cities
Litchfield Park, Arizona • Searcy, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

NCT00634842
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
66
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 15, 2026, 9:49 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

mHealth Titration and Management

NCT03908762
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Complication
Interventions
iSage App with connected glucometer, Magnet
Device · Behavioral
Lead sponsor
Amalgam Rx, Inc.
Industry
Eligibility
21 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

NCT00104182
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin NPH
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

NCT01269047
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide, Exenatide, Insulin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

NCT01850615
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, basal insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 15, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Results available

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

NCT00537303
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Fresno, California • Mission Viejo, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 15, 2026, 9:49 PM EDT